Although it is doubtful that LMP1-specific CAR-T cells can target cancer cells in NPC with much lower LMP1 expression, these results are encouraging (125, 126), and a clinical trial for LMP1-specific CAR-T cells to treat EBV-associated malignant tumors is underway (NCT02980315). Here, PDLIM7 is linked to nasopharyngeal carcinoma.